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Summary
AIMS OF THE STUDY: Combination antiretroviral therapy
(cART) has reduced mother-to-child transmissions
(MTCT) and improved the prognosis of HIV-infected new-
borns. However, drug resistance mutations (DRM) in HIV-
infected children, either transmitted by MTCT (HIV-tDRM)
or selected by suboptimal adherence and drug levels (HIV-
sDRM), remain a concern. We sought to determine the
rate of HIV-tDRM and HIV-sDRM in MTCT pairs in
Switzerland.
METHODS: We performed a retrospective analysis of
prospectively collected clinical data and available stored
samples from MTCT pairs participating in the Swiss Moth-
er-Child HIV (MoCHIV) cohort.
RESULTS: We identified 22 HIV-infected mother-child
pairs with delivery between 1989 and 2009 who had 15
years of follow-up (33% white ethnicity). Twenty-one
women (96%) were treatment-naïve before pregnancy, 8
(36%) had an unknown HIV status and delivered vaginally,
2 were diagnosed but not treated, and 11 (50%) received
antiretrovirals during pregnancy or at delivery, of whom
only 6 cases (27%) had cART. HIV subtypes were con-
cordant in all mother-child pairs (subtype B 13/22 [59%]).
Using stored plasma (n = 66) and mononuclear cell (n =
43) samples from the children, HIV-tDRM (M184V) was
identified in 1 of 22 (4.5%) mothers (1/11 treated, 9%)
and was followed by HIV-sDRM at 10 months of age. HIV-
sDRM (M184V 23%; K103N 4.5%; D67N 13.6%) occurred
in 16/22 (73%) after 4 years, half of whom were treatment
naïve. HIV-sDRM were associated with a lower CD4 T-cell
nadir (p <0.05) and tended to have higher viral loads and
more frequent cART changes.
CONCLUSIONS: HIV-tDRM were low in this Swiss
MoCHIV cohort, making them a minor yet preventable
complication of prenatal HIV care, whereas HIV-sDRM are
a significant challenge in paediatric HIV care.
Keywords: mother-to-child transmission, drug resistance
mutation, HIV-tDRM, HIV-sDRM, combination antiretrovi-
ral therapy
Introduction
Mother-to-child transmission (MTCT) accounts for more
than 90% of HIV infections during childhood according
to UNAIDS reports [1, 2]. Missed maternal diagnosis and
non-treatment are the main causes of MTCT. These are
preventable by a combination of measures consisting of
early HIV testing for all women as part of routine prenatal
care, immediate combined antiretroviral treatment (cART)
and regular monitoring throughout pregnancy. Complete
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HIV load suppression by the third trimester, and specif-
ically at the time of delivery, reduces the risk of trans-
mission to almost zero. As outlined by the WHO (Pre-
vention of MTCT – PMTCT) and European guidelines [3,
4], treatment-naïve women should start cART immediate-
ly, with an integrase strand transfer inhibitor (INSTI)-con-
taining regimen being the preferred treatment. Pregnant
women already under suppressive cART should continue,
but contraindicated drugs such as didanosine, stavudine
or triple nucleoside reverse transcriptase inhibitor (NRTI)
combinations should be replaced. The latest data from the
IMPAACT (International Maternal Pediatric Adolescent
AIDS Clinical Trials Network) study suggest that exposure
of mothers to dolutegravir (DTG) at the time of conception
could be associated with a higher risk of neural tube de-
fects. Therefore, the Swiss HIV Cohort Study (SHCS) ad-
vises against prescribing DTG for women who are trying
to become pregnant [5].
In case of incomplete suppression (HIV-VL >50 copies
(cp)/ml) at 34-36 weeks of gestation, intravenous zidovu-
dine administration should be considered during labour
and Caesarean section. In the case of ongoing maternal vi-
ral replication, international guidelines recommend start-
ing cART in high-risk newborns as soon as possible and
advocate lifelong continuation in the case of confirmed
MTCT [4, 6, 7]. Recent studies indicate that starting cART
at birth is associated with improved long-term outcomes
for HIV-infected children [8, 9]. Accordingly, morbidity
and mortality in HIV-infected children have significantly
decreased in the recent decades [10].
HIV-infected children in Western Europe and North Amer-
ica benefit from easy access to specialised medical care
which provides laboratory monitoring and cART [11].
Moreover, novel drugs and combinations have facilitated
cART for pregnant women and children alike, allowing the
goal of long-term HIV suppression with outstanding bene-
fits for health at the individual, societal, and epidemiologi-
cal levels to be reached.
Nevertheless, virological failure remains a key challenge
in the management of HIV-infected children. The rates of
virological failure range from 12% to 32% in high and
limited-resource settings, respectively. Rates peak during
infancy, again during adolescence, and then when transi-
tioning to adult medical care [12–14]. Although dosing of
cART in children is sometimes difficult because a suitable
drug formulation (e.g. suspension) is not available, viro-
logical failure reflects not only a lack of access to care
and cART or toxicity concerns, but often also adherence is-
sues of both mothers and children. Thus, a main challenge
in HIV-infected children is the emergence of HIV vari-
ants with drug resistance mutations (DRM), either selected
by suboptimal adherence and insufficient drug combina-
tions and levels (HIV-sDRM), or originating from MTCT
(HIV-tDRM). For the reasons pointed out earlier, the risk
of HIV-sDRM increases during the HIV-infected child’s
lifetime [14]. Conversely, MTCT may involve HIV-tDRM
[15], which may also impact cART efficacy and favour the
emergence of HIV-sDRM. Here, we report the results of a
retrospective analysis of data and blood samples collected
prospectively from MTCT pairs participating in the Swiss
Mother and Child HIV Cohort Study (MoCHIV) in order
to evaluate the rate of transmitted and selected HIV drug
resistance in Switzerland.
Materials and methods
Study design
Data and blood samples were collected prospectively by
MoCHIV, in which 277 HIV-infected children have been
enrolled since 1989. These children were followed in clin-
ics in Basel, Bern, Genève, St Gallen, Zurich and Ticino
[16]. MoCHIV is approved by the Swiss Federal Office
of Public Health and by the institutional review boards of
the participating centres. All women gave their written in-
formed consent to participate in the study, including the
retrospective analysis of their and their children’s
anonymised data and stored material. In June 2017, 274
ldren had been registered in Switzerland as being born to
HIV-infected mothers (see MoCHIV on SHCS website).
Of these, 1559 children were diagnosed as being not infect-
ed with HIV-1, 145 children had an undefined HIV-status,
and 277 children were HIV-1 infected and participated in
the Swiss MoCHIV. Of the HIV-positive children, 72 were
lost from follow-up or are being treated by a non-cohort
physician, 62 have died, and 59 are currently under follow-
up in MoCHIV.
For inclusion in this virological DRM study, we identified
all MTCT pairs enrolled in the MoCHIV cohort from
whom samples were available from the mothers at the
time of pregnancy and/or within one year postnatally, and
from the corresponding MoCHIV follow-up visits of the
children. We analysed demographic, clinical and labora-
tory parameters including plasma HIV load, CD4 T-cell
counts, cART, adherence and clinical conditions, as well as
prospectively cryopreserved plasma and whole-blood sam-
ples. All available genotype and drug resistance profiles
previously performed were included in the analysis. In ad-
dition, HIV-DRM were identified by HIV genotyping and
resistance testing of the samples from mothers and chil-
dren at the time of, or shortly after, birth in the Laboratory
for Genotyping and Resistance Testing (formerly Division
of Infection Diagnostics, Department Biomedicine, Uni-
versity of Basel, accreditation STS219; from 1 Jan 2019:
Clinical Virology, Laboratory Medicine, University Hos-
pital Basel, STS0568) to identify tDRM. HIV-tDRM were
defined as DRM detected post-natally in RNA or proviral
DNA samples that had been obtained before any antiretro-
viral treatment was administered and which matched the
mother’s viral genotype. HIV-sDRM were defined as new
DRM arising in children with virological failure.
HIV genotyping and resistance testing
The standard of care of HIV genotyping and resistance
testing in our institution is Sanger sequencing of amplicons
generated from the HIV protease, reverse transcriptase
and, since 2012, the integrase genes. This analysis was per-
formed on both plasma and/or peripheral blood mononu-
clear cell (PBMC) samples by generating amplicons using
the Abbott ViroSeq HIV-1 Genotyping kit (Abbott, IL,
USA) or in-house methods validated and accredited in
the Division of Infection Diagnostics, Department Bio-
medicine, University of Basel (STS219). Briefly, follow-
ing nested PCR and quality control by agarose gel elec-
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trophoresis, the amplicons were purified with illustra
ExoProStar 1-Step (GE Healthcare, England). The se-
quencing was performed using the BigDye Terminator
v3.1 cycle sequencing kit (Thermo Fisher Scientific, MA,
USA), purification with Sephadex G-50 (GE Healthcare,
England) and capillary electrophoresis on a 3500 Genetic
Analyzer (Thermo Fisher Scientific, MA, USA). The se-
quences were analysed using SmartGene (Lausanne,
Switzerland) [17] and the results interpreted using the HIV
Drug Resistance Database of Stanford University (CA,
USA). As an accredited regional HIV reference laboratory,
the Laboratory for Genotyping and Resistance Testing par-
ticipates in an external quality assurance program using the
French ANRS.
Additionally, deep sequencing using the Illumina MiniSeq
platform (CA, USA) was performed on 10 samples from
three mother and child pairs. HIV protease, reverse tran-
scriptase and integrase were first amplified using nested
PCR primers, followed by library preparation using the Il-
lumina Nextera XT kit (CA, USA). Paired-end sequenc-
ing was performed using the Illumina MiniSeq MidOutput
Kit and a read length of 150bp. Reports were generated by
DeepChek-HIV (ABL, Luxembourg) [18]. Proviral load
was determined using DNA extracted from the collected
PBMCs using a quantitative, real-time PCR assay with
normalisation to 150,000 cells using aspartoacylase, a hu-
man diploid housekeeping gene routinely used for this pur-
pose [19].
Data analysis
Patient demographics and laboratory parameters were
analysed using descriptive statistics. Data from each indi-
vidual child were described longitudinally over time. De-
mographic characteristics of mother-child pairs are pre-
sented as proportions (percentages) or as medians (25th,
75th; range), using box and whisker plots where indicated.
Categorical variables were compared using the unpaired t-
test and Fisher’s exact test, whereas continuous variables
were analysed using the Wilcoxon rank-sum test. Two-
sided p-values of <0.05 were considered statistically sig-
nificant. Analyses were performed using the statistical
software package SPSS version 24 (IBM® SPSS Statistics
24.0.0.1) and Excel version 15.37 (Microsoft® Excel 2016
for Mac).
Results
We identified 22 MTCT pairs which fulfilled the enrol-
ment criteria in the Swiss MoCHIV study. The children
were born between 1989 and 2009, thereby covering 20
years of different treatments and antiretroviral drug avail-
abilities. Nineteen children are still enrolled in this national
cohort and three have moved to the adult Swiss HIV Co-
hort Study (SHCS). Median gestational age at delivery was
38 weeks (25th percentile 28, 75th percentile 39, range
27–42 weeks) and 27% of the children were born pre-
maturely (<37 weeks) (table 1). Eight of the 22 children
(36%) were delivered vaginally. All but one of the mothers
(21/22, 95%) reported as treatment-naïve before pregnan-
cy. During pregnancy, only 11 (50%) mothers received any
kind of antiretroviral therapy (zidovudine in five cases,
table 1), and cART was administered to only 6 (27%)
mothers. Plasma HIV load at the time of delivery was
only available for 10 mothers, and none of them were sup-
pressed to <50 cp/ml (median 71,249 cp/ml; table 1).
The demographics of the HIV-infected children are sum-
marised in table 2. To the best of our knowledge, there
were no siblings in this analysis, but this was not due to ex-
plicit exclusion. Five (23%) children had detectable plas-
ma HIV loads at birth or within the first month, suggest-
ing in utero transmission (median HIV load 13,845 cp/
ml; range 6880–2,531,122). In another 14 children, the
first plasma HIV loads were detected within the first nine
months of life. Only one child had undetectable HIV loads
at six months of age, whereas the other children had me-
dian plasma HIV loads of 200,000 cp/ml (IQR
16,274–765,085; range 748–2,531,122). During follow-up
visits, the nadir CD4 T-cell count varied widely, between
14 and 1,282/μl (median 280; IQR 146–627). Peak HIV
loads at the time of diagnosing virological failure ranged
from 1160 to 7,400,000 cp/ml (median 424,913; IQR
64,831–958,025). At last follow-up (median 14 years old;
IQR 14–18 years; range 6–23 years), 19 of the 22 children
were alive and attending regular follow-up (one child died
at one year of age, two children were lost to follow-up at
Table 1: Clinical characteristics of mothers in MTCT pairs.
Variables n (%) or median 25th, 75th percentiles (range)
Gestational age at delivery (weeks) 38 28, 39 (27–42)
Type of delivery Vaginal 8 (36)
Caesarean 11 (50)
Unknown 3 (14)
Maternal complication at delivery Haemorrhage 2 (9)
Infection 4 (18)
Other 2 (9)
ART during pregnancy Yes 11 (50)
Duration ≤1month 8 (73)
Duration >1month 3 (27)
Type of therapy / prophylaxis cART 6 (27)
ZDV 3 (14)
ZDV intrapartum 2 (9)
None 11 (50)
CD4 T cell at birth (cells/μl) 308 72, 580 (32–822)
HIV load at birth (copies/ml) 71,249 9840, 132,621 (204–284,000)
cART = combination antiretroviral therapy; ZDV = zidovudine
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9 and 10 years old), and 16 of these 19 children were on
cART. The CD4 cell counts had a median of 709 cell/mmc
(IQR 555–848; range 240–1,300). Plasma HIV loads were
below the limit of detection (<20 cp/ml) in 11/19 children
(median 60 cp/ml; IQR 0–77; range 0–10,000).
Antiviral treatment and virological failure
Thirteen (59%) children were born before the year 2000.
Individual infant treatment history from the start of ART is
summarised in figure 1. All children, except one who died
within the first year of life, had a follow-up longer than two
years. Among children who received cART, there was an
average of five treatment changes (median; IQR 3–8; range
2–16) (table 2). Virological failure occurred in all chil-
dren during follow-up (median 2; IQR 2–3.5; range 1–6).
Adjusting the observational data for the year of effective
follow-up indicated an average of 0.18 virological failure
episodes per year and child, i.e., a virological failure oc-
curred once every five years of observation time on aver-
age. Approximately half the virological failure events were
among those older than eight years of age. In three chil-
dren, plasma HIV loads were detectable over prolonged
periods of more than 10 years.
Genotype and drug resistance profile
A total of 165 genotypic resistance profiles were analysed.
One third of them (56/165) had been performed previously
during a routine visit. For 33 profiles, only partial se-
quences were available, and these needed to be repeated.
Complete sequences of sufficient quality were available
for a total of 109 samples, consisting of 66 plasma- and
43 PBMC-derived sequences. Concordant HIV-1 subtypes
were observed in all mother-child pairs, the most prevalent
being subtype B in 13/22 (59%) (fig. 2). Other subtypes
and recombinant strains included C in 18% (4/22) of moth-
er-child pairs and AC, A1C, A1, CRF18_cpx and
CRF67_01B in 4.5% (1/22) each. Since protease inhibitors
were the first antiretrovirals to be used in cART in Switzer-
land in 1996 [20], we used HIV-protease sequences as a
surrogate of diversity and evolution over time. In the cir-
cular phylogram of mother and child viral RNA and provi-
ral DNA sequences (fig. 2), examples of viral evolution
are visualised in the distance between branches, which are
still clustered within their respective HIV-1 subtypes. HIV
polymorphisms and sequences not conferring intermedi-
ate to high-level antiretroviral resistance were detected in
all children (not shown). HIV resistance genotypes confer-
ring relevant intermediate to high-level antiretroviral resis-
tance were found in 45% (10/22) of the mothers, affecting
susceptibility to protease inhibitors (PI) in seven (70%),
to NRTI in one (10%), to non-nucleo(s/t)ide reverse tran-
scriptase inhibitors (NNRTI) in three (30%), and to INSTI-
containing therapy in one (10%).
HIV-tDRM were identified in one of the 22 MTCT pairs
(4.5%), showing matched mother- and child-derived HIV
sequences (1 of 11 ART-exposed mothers, 9%). The pres-
ence of HIV-tDRM was associated with early emergence
of HIV-sDRM (0.83 vs 3.5 years after birth), but the small
numbers precluded a meaningful statistical analysis.
The emergence of HIV-sDRM was seen in 16/22 (73%)
children, at a mean age of 4.3 years (median 2.8; IQR
0.8–5.9; range 0.25–14.8), and 10/22 (45%) had two or
more mutations. Thirteen of these 16 (81%) were on treat-
ment at the time of HIV-sDRM emergence. Children with
HIV-sDRM showed a trend towards a greater number of
treatment changes over the entire follow-up period com-
pared to children without HIV-sDRM (7 vs 4 times, respec-
tively; p = 0.104). The CD4 T-cell nadir was lower and
associated with higher HIV loads in children with HIV-
sDRM (p <0.05 and p = 0.06, respectively; fig. 3).
The most frequent DRM was M184V, detected in 7/22
(32%), while other major NRTI mutations (M41L, L210W,
Table 2: Demographics of the HIV-infected children.
Variables n (%) or median 25th, 75th percentiles (range)
Total 22 (100)
Gender (female) 11 (50)
Ethnicity White 7 (32)
Black 8 (36)
Other 7 (32)
HIV-1 subtype B 13 (59)
Non-B 9 (41)
Peak HIV load (copies/ml) 424,914 64,831, 958,025
(1160–7,400,000)
Nadir CD4 T cell (cells/μl) 280 146,627 (14–1,282)
Antenatal prophylaxis (yes) 8 (36)
Age of the children at ART start At birth 10 (45)
Not at birth but ≤1year 7 (32)
Later >1year 4 (18)
Never 1 (5)
Initial HIV treatment ART 11 (50)
cART 10 (45)
No therapy 1 (5)
CD4 T-cells at ART start (counts/μl) 1,579 379, 2,45
(65–2,649)
HIV load at ART start (copies/ml) 181,256 13,278, 602,277
(0–8,829,994)
ART changes (number) 5 3, 8 (2–16)
ART = antiretroviral therapy; cART = combination antiretroviral therapy
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T215FY, L219E, L74V, V75M) were seen only in one or
two patients. Considering DRM associated with low-level
or intermediate resistance, D67N was the most prevalent,
detected in 14% of children (3/22), followed by K70R, de-
tected in only one patient (4.5%). A wide range of NNR-
TI DRM were found (K101E, K103N, V106M, G190E,
P225H, M230L) at a rate of 4.5% each. PI DRM were most
commonly M46I, followed by V82A and I54V. Only one
major INSTI DRM (R263K) was detected, in one child in
a proviral sequence, while minor INSTI DRM were found
in a total of six patients. However, clinical evidence of as-
sociated virological failure was lacking, as none of the pa-
tients were exposed to this class of drugs. In all but two
cases, HIV-DRM emerged after previous exposure ranging
Figure 1: Individual antiretroviral treatment history of vertically HIV-infected children. HIV treatment history over eight years of follow-up
is shown. Patients 18 and 21 were analysed by deep sequencing, as described in more detail in the results section, and patient 20 is shown in
figure 4. The date of birth is indicated in front of the corresponding time line. Each coloured bar represents a type of treatment. A black bar
means no treatment and a grey bar means data not available. Time is represented on the x axis, and the length of a bar corresponds to the in-
terval of treatment, including when it was started.3TC = lamivudine; AZT = zidovudine; FTC = emtricitabine; ABC = abacavir; DDI = didano-
sine; DDC = zalcitabine; D4T = stavudine; TDF = tenofovir; EFV = efavirenz; ETV = etravirine; DRV = darunavir; LPV = lopinavir; NFV = nelfi-
navir; ATV = atazanavir; RTV/r = ritonavir; DTG = dolutegravir; RGV = raltegravir
Figure 2: Circular phylogram of mother and child viral RNA and proviral DNA sequences. The diversity and evolution of HIV-1 protease
sequences from RNA and proviral DNA over time is shown. Sequences that cluster together due to common origin and subtype are marked in
different colours for subtype B, subtype C, subtype CRF18_cpx, subtype A1, subtype A1C, and subtype CRF67_01B.M = mother; C = child; R
= RNA; P = proviral DNA; date = sampling date
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from six months to 10 years. DRM were already present
at the time of the first genotypic analysis (M184V, T215Y,
L210W, M230I) in only two children without medical his-
tory of prior ART.
Figure 3: HIV load and CD4 T-cell count in vertically HIV-in-
fected children. A. CD4 T-cell count in MTCT children at birth with
and without selected HIV drug resistance mutations (HIV-sDRM).
B. Nadir CD4 T-cell count in MTCT children with and without HIV-
sDRM. C. First HIV-1 load in MTCT children with and without HIV-
sDRM. D. Peak HIV-1 load in MTCT children with and without HIV-
sDRM. Box and whiskers plots showing median and 25th and 75th
percentiles.
In three MTCT pairs, 10 sample materials from the time
of delivery were available in sufficient amounts to com-
plement the conventional Sanger sequencing by next-gen-
eration sequencing (NGS). In pair 21, no additional DRM
were found. In pair 18, DRM M184I and V, 41L, 65R,
67N, 70R, 74I, 210W and 215Y were detected at frequen-
cies of 53.7% (1,300 reads) and 22.7% (551 reads), 63.7%
(557 reads), 1.2% (22 reads), 70.6% (1,282 reads), 1.2%
(25 reads), 3% (64 reads), 4.1% (46 reads) and 70% (609
reads), respectively. None of the variants with frequencies
of <4% were seen by amplicon-directed Sanger sequenc-
ing. In pair 20, NGS identified the PI resistance 82A at
a rate of 16.5% (44,670 reads) during the time when the
child had persistent high HIV loads having been exposed
to this drug class. The PI resistance 82A increased to a de-
tection rate of 99.6% (147,899 reads) two years later with
the same method, and at that time was also identified by
Sanger sequencing (fig. 4).
Discussion
In this study of the Swiss MoCHIV cohort, we analysed
HIV-1 genotype and drug resistance profiles in data and
blood samples collected prospectively from 22 HIV infect-
ed mother-child pairs. The rate of HIV-tDRM was one out
of all 22 MTCT pairs (4.5%) and 1/11 (9%) MTCT pairs
where mothers had been previously exposed to antiretrovi-
rals. Although the overall study population was too small
for more robust conclusions, other studies have reported
rates between 4.9% and 17% [21–23]. The HIV-tDRM de-
tected affected the HIV reverse transcriptase through the
M184V mutation.
Conversely, the rate of HIV-sDRM was 16/22 (73%), em-
phasising that HIV-sDRM represent a significant issue in
Figure 4: Deep sequencing of samples from mother-child pair 20. Comparison of Sanger sequencing and deep sequencing results of
HIV-1 RNA from mother-child pair 20. Sampling dates and treatment history are indicated, as well as HIV-1 loads (copies / mL). Deep se-
quencing results are additionally shown as mutation frequencies (%). No material was available from the first time point at which the reported
M184I was detected.NRTI = nucleo(s/t)ide reverse transcriptase inhibitor; NNRTI = non-nucleo(s/t)ide reverse transcriptase inhibitor; PI = pro-
tease inhibitor; 3TC = lamivudine; ZDV = zidovudine; DDI = didanosine; TDF = tenofovir; EFV = efavirenz; NFV = nelfinavir; DRV = darunavir;
TPV = tipranavir; RTV/r = ritonavir/boosted ritonavir
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paediatric HIV care. The predominant mutation among
HIV-sDRM was M184V (32%), but other mutations af-
fecting other drugs and classes were also found at varying
rates, including TAMs (M41L, L210W, T215FY, L219E in
4.5 to 9%; D67N in 14%; K70R in 4.5%), discriminato-
ry and nonpolymorphic NRTI mutations L74V and V75M,
mutations affecting PIs (M46I in 18%; V82A and I54V
in 9%) and NNRTIs (K101E, K103N, V106M, G190E,
P225H, M230L in 4.5%). Only one case of INSTI DRM
was found, in line with the study period of up to 2014,
an era before the widespread availability of INSTIs in
Switzerland. Although antenatal screening for HIV infec-
tion is recommended in Switzerland, eight women were
not known to be HIV-infected during pregnancy and deliv-
ery, and the three remaining women did not receive anti-
retroviral prophylaxis during pregnancy for unknown rea-
sons. Revisiting the MoCHIV data from the last 20 years,
there was only one registered case of vertical HIV trans-
mission after 2009, which occurred in 2011 (see MoCHIV
on SHCS website, fig. 3). Together with the reduced rate
of MTCT, the rate of HIV-tDRM is expected to decrease
in Switzerland, but this cannot be generalised to other set-
tings, e.g. resource-limited countries.
HIV-sDRM emerged on average three years after birth and
was associated with more frequent treatment changes (p =
0.104), lower CD4 T-cell nadir (p <0.05) and higher peak
plasma HIV loads (p = 0.06). In the one case of HIV-
tDRM, HIV-sDRM were subsequently detected after 10
months, suggesting that transmitted drug resistance might
facilitate much earlier HIV-sDRM emergence and virolog-
ical failure, although further analyses are needed due the
low sample size. The first report on HIV-tDRM was pub-
lished in 1994, describing a case of neonatal infection by a
zidovudine-resistant HIV-1 strain [24]. In a systematic re-
view published in 2014, HIV-tDRM data among treatment-
naïve children were only available from 14 countries, but
the overall number of cases analysed was low [25]. As ex-
pected, the type and prevalence of HIV-tDRM reflected the
choice and availability of antiviral treatments in the respec-
tive countries. Historically, the low cost of nevirapine ad-
ministered as a single dose to the mother during labour and
to the child right after delivery allowed its widespread use
and improved the prevention of MTCT in low resource set-
tings. Unfortunately, rapid selection of resistant viral mu-
tants was soon observed [26, 27]. In high-income coun-
tries, HIV-tDRM of 10% to 17% have been estimated [15].
A recent study investigated both selected and transmitted
HIV drug resistance and indeed found a rate of 4.9% in
the latter group [22]. However, the data originated from
a small cross-sectional study of 19 families and did not
compare HIV-tDRM and -sDRM. There are few data on
the role of HIV-tDRM, even though they potentially have
effects on virological failure and the emergence of HIV-
sDRM when only limited options for new antiretroviral
drug classes exist.
Our in-depth analysis of HIV-DRM by NGS was limited to
three patients with sufficient sample materials. The three
cases were representative of three different scenarios. In
two cases, HIV-DRM at frequencies below 20% that were
not detected by Sanger sequencing were detectable by deep
sequencing. However, in one case the HIV-sDRM emerged
as a majority variant after two years and was then detected
by Sanger sequencing. Thus, NGS could be helpful for the
identification of DRM-minority variants and for monitor-
ing them over time. In the absence of DRM-informed deci-
sions about effective cART, at least two new antiretrovirals
that have not been used previously to treat either mother
or child should be considered for children with virological
failure [28].
Thus, the results of this study indicate that in the reported
group of children, HIV-tDRM were found in only one out
of 22 HIV-infected children born to mothers not receiving
ART before and receiving it rarely during pregnancy (six
with cART). In contrast, the frequency of HIV-sDRM was
high and occurred with three to five years, despite the fact
that half the children were treatment naïve.
This study has several limitations. Firstly, the number of
available mother-child pairs was small, limiting the statis-
tical analysis to the descriptive level, even though a long
follow-up of 15 years was available. Secondly, this is a
retrospective evaluation which included patients from a
range of different eras of HIV diagnosis and management
from the years 1989–2009, including the pre-ART and pre-
cART eras. Thirdly, apparently treatment-naïve women ap-
peared overrepresented among the 22 MTCT pairs, but this
result emerged only because of this detailed analysis. How-
ever, we remain cautious by not directly attributing a low
pre-test risk of HIV-tDRM to a patient history of no prior
ART exposure. In some cases, there was no specific ART
history available, whereas in others, this information may
not have been reliable, given the stigma in patients with a
difficult psycho-social history, including a migration back-
ground. Moreover, the transmission of drug-resistant virus-
es remains a possibility, especially in the early era of ART
when insufficient suppression was usual. In this respect, it
is notable that 60% of the MTCT pairs had the B subtype
(fig. 2), but the 68% were of non-white ethnicity. Fourth-
ly, HIV load and resistance testing could not be performed
at all time points of interest, even though a significant ef-
fort was made by processing 109 samples of plasma and
PBMC in addition to the HIV load data and resistance data
that had been obtained at the time of the historic follow-
up in the routine clinic. As the blood samples from these
new-borns and infants were limited in size, additional next
generation deep sequencing could not be performed except
in 10 samples obtained from three cases. Nevertheless, the
case studies were informative in principle, demonstrating
that either no additional DRM were detectable (scenario 1),
that DRM were detectable as minority species, but did not
emerge as majority species (scenario 2), or that DRM were
detectable as minority species and emerged as majority
species during follow-up (scenario 3). Thus, HIV genotyp-
ing and resistance testing may provide relevant guidance
for treatment, but access and adherence to appropriately
dosed antiretrovirals, including new, not previously pre-
scribed drug classes such as integrase inhibitors and com-
binations, remains an important consideration throughout
paediatric HIV care.
Conclusions
While acknowledging these limitations, we conclude that
HIV-tDRM were low in this Swiss study of mother-to child
HIV transmission, making it a minor yet today preventable
complication of HIV care [29, 30]. However, HIV-sDRM
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remain an important issue in paediatric HIV care, under-
pinned by the fact that all options were available for the
treatment-naïve children in our study. Indeed, similar to
the paediatric care of other chronic medical conditions [31]
such diabetes mellitus [32] and transplantation [33], non-
adherence in paediatric HIV care remains challenging de-
spite more potent drugs, lower pill counts and fewer side
effects in the current era of cART [14].
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